Concomitant use of VENCLEXTA with strong CYP3A inhibitors at initiation and during the ramp-up phase is contraindicated in patients with CLL due to the potential for increased risk of tumor lysis syndrome [see Dosage Modifications for Drug Interactions under Dosage & Administration; Effects of Other Drugs on VENCLEXTA under Interactions].
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
